Get started
Author

Victoria J. Savage

Observed names: V Savage, V. Savage, Victoria J Savage, Victoria Savage
ORCID: 0000-0002-5381-0731
Observed ORCID: 0000-0002-5381-0731
OpenAlex ID: A5033052791
Staphylococcus aureus Biofilms Promote Horizontal Transfer of Antibiotic Resistance
2013 · Victoria J. Savage, Ian Chopra, et al. · Antimicrobial Agents and Chemotherapy · 359
PDF
Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria
2017 · Cédric Charrier, Anne-Marie Salisbury, et al. · Antimicrobial Agents and Chemotherapy · 46
PDF
Population Diversification in Staphylococcus aureus Biofilms May Promote Dissemination and Persistence
2013 · Victoria J. Savage, Ian Chopra, et al. · PLoS ONE · 35
PDF
Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV
2016 · Victoria J. Savage, Cédric Charrier, et al. · Journal of Antimicrobial Chemotherapy · 28
Discovery of the first inhibitors of bacterial enzyme d-aspartate ligase from Enterococcus faecium (Aslfm)
2013 · Veronika Škedelj, Andrej Perdih, et al. · European Journal of Medicinal Chemistry · 22
Restoring carbapenem efficacy: a novel carbapenem companion targeting metallo-β-lactamases in carbapenem-resistant Enterobacterales
2020 · Nicola Ooi, Victoria E Lee, et al. · Journal of Antimicrobial Chemotherapy · 20
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase
2018 · David H. McGarry, Ian R. Cooper, et al. · Bioorganic & Medicinal Chemistry Letters · 18
PDF
Discovery and structure–activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors
2022 · Amanda Lyons, James Kirkham, et al. · Bioorganic & Medicinal Chemistry Letters · 16
Discovery and structure–activity relationships of a novel isothiazolone class of bacterial type II topoisomerase inhibitors
2016 · Ian R. Cooper, Andrew J. McCarroll, et al. · Bioorganic & Medicinal Chemistry Letters · 11
PDF
Efficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae Infection
2016 · Victoria J. Savage, Cédric Charrier, et al. · Antimicrobial Agents and Chemotherapy · 10
Evaluating the druggability of TrmD, a potential antibacterial target, through design and microbiological profiling of a series of potent TrmD inhibitors
2023 · Andrew J. Wilkinson, Nicola Ooi, et al. · Bioorganic & Medicinal Chemistry Letters · 9
In vitrobiological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases
2016 · Cédric Charrier, Anne-Marie Salisbury, et al. · Journal of Antimicrobial Chemotherapy · 9
Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1
2020 · R. Kirk, A. Ratcliffe, et al. · RSC Medicinal Chemistry · 5
Evaluation of Homogentisic Acid, a Prospective Antibacterial Agent Highlighted by the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) Clinical Trial
2023 · Nicola Ooi, Ian R. Cooper, et al. · Cells · 3
PDF
Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 2
2020 · R. Kirk, A. Ratcliffe, et al. · RSC Medicinal Chemistry · 2
PDF
Late Breaking Abstract - Exciting phase 1 data on RESP-X, a novel monoclonal antibody targeting a key virulence mechanism of Pseudomonas aeruginosa, with potential as a treatment to reduce exacerbations in non-CF bronchiectasis
2024 · Colm Leonard, Victoria Savage, et al. · European Respiratory Journal · 1
Late Breaking Abstract - Disarming Pseudomonas aeruginosa (Pa): phase 2a Evidence for safe and tolerable Pa type 3 secretion system (T3SS) Blockade in non-cystic fibrosis bronchiectasis (NCFB)
2026 · Colm Leonard, Juergen Dobmeyer, et al. · European Respiratory Journal
D92-10 Positive Phase 2a Study Results on Resp-x (infex702), a Highly Potent Anti-virulence Monoclonal Antibody in Development to Reduce Exacerbation Frequency in Pseudomonas Aeruginosa-colonised Non-cystic Fibrosis Bronchiectasis (ncfb) Patients
2026 · C T Leonard, J Dobmeyer, et al. · American Journal of Respiratory and Critical Care Medicine
Works count: 18
Citation count: 594
H-index: 10
I10-index: 10
Year
Topic
Type